Patent application number | Description | Published |
20110105410 | Beta-Turn Peptidomimetic Cyclic Compounds for Treating Dry Eye - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 05-05-2011 |
20120165271 | METHODS OF TREATING RETINITIS PIGMENTOSA - The present invention relates to methods of treating retinitis pigmentosa using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs useful in treating retinitis pigmentosa. | 06-28-2012 |
20120322747 | BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS FOR TREATING DRY EYE - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 12-20-2012 |
20140274910 | BETA-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS FOR TREATING DRY EYE - The present invention relates to methods of treating dry eye using β-turn peptidomimetic cyclic compounds or derivatives thereof. The β-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye. | 09-18-2014 |
Patent application number | Description | Published |
20090131511 | PALMARUMYCIN BASED INHIBITORS OF THIOREDOXIN AND METHODS OF USING SAME - Embodiments of the present invention relate to inhibitors of thioredoxin. Certain embodiments relate to palmarumycin based compounds and methods of using the same. Such compounds may be useful in inhibiting the overexpression of thioredoxin, inhibiting tumor growth and treating cancer. | 05-21-2009 |
20100063129 | METABOLITES OF WORTMANNIN ANALOGS AND METHODS OF USING THE SAME - Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein. | 03-11-2010 |
20100166724 | USES OF THIOREDOXIN - The present invention relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth. | 07-01-2010 |
20100249205 | Metabolites of Wortmannin Analogs and Methods of Using Same - Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein. | 09-30-2010 |
20110045080 | Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto - The present invention includes single-walled carbon nanotube compositions for the delivery of siRNA and methods of making such single-walled carbon nanotube compositions. A single-walled carbon nanotube composition for delivery of siRNA includes a nonfunctionalized single-walled carbon nanotube; and siRNA noncovalently complexed with the nonfunctionalized single-walled carbon nanotube, wherein the siRNA solubilizes such nonfunctionalized single-walled carbon nanotube. | 02-24-2011 |
20110092595 | Compositions and Methods for Treating Lung Cancer - Embodiments of the present invention provide compositions and methods for treating lung cancer, including small cell and non-small cell lung cancer that may express HIF-1a by administering a therapeutically effective amount of PX-478. | 04-21-2011 |
20110110941 | Wortmannin Analogs and Methods of Using Same in Combination with Chemotherapeutic Agents - Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer. | 05-12-2011 |
20110144066 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME - Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. | 06-16-2011 |
20110263672 | Metabolites of Wortmannin Analogs and Methods of Using the Same - Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein. | 10-27-2011 |
20120226031 | PALMARUMYCIN BASED INHIBITORS OF THIOREDOXIN AND METHODS OF USING SAME - Embodiments of the present invention relate to inhibitors of thioredoxin. Certain embodiments relate to palmarumycin based compounds and methods of using the same. Such compounds may be useful in inhibiting the overexpression of thioredoxin, inhibiting tumor growth and treating cancer. | 09-06-2012 |
20130058984 | SINGLE-WALLED CARBON NANOTUBE/BIOACTIVE SUBSTANCE COMPLEXES AND METHODS RELATED THERETO - The present invention includes single-walled carbon nanotube compositions for the delivery of siRNA and methods of making such single-walled carbon nanotube compositions. A single-walled carbon nanotube composition for delivery of siRNA includes a nonfunctionalized single-walled carbon nanotube; and siRNA noncovalently complexed with the nonfunctionalized single-walled carbon nanotube, wherein the siRNA solubilizes such nonfunctionalized single-walled carbon nanotube. | 03-07-2013 |
20130184317 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME - Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. | 07-18-2013 |
20150126563 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME - Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein. | 05-07-2015 |
Patent application number | Description | Published |
20090251749 | OVD CONTAINING DEVICE - A holographic overlay is provided, including: a polycarbonate substrate having a first side and a second side, a diffractive structure cast upon the first side of the polycarbonate substrate, and a reflection-enhancing coating on at least a part of the diffractive structure; wherein the second side of the polycarbonate substrate provides a substantially flat external surface of the overlay capable of fusing to a conforming surface in the presence of heat and pressure without an adhesive. Optionally, the overlay is laser-engraved so as to form ablated voids in the metal coating and carbonize the laser engravable polycarbonate under the ablated voids. According to another aspect of the invention, a metal coating on a hologram is made substantially transparent using a laser to form a transparent portion of a hologram. Optionally, it is done after applying the hologram to an object such as a card, a document, etc., in register with underlying information to ensure its visibility and continuity of the hologram. | 10-08-2009 |
20130082458 | OVD CONTAINING DEVICE - A holographic overlay is formed using casting a diffractive structure upon a first side of a polycarbonate substrate, and providing a reflection-enhancing coating on at least a part of the diffractive structure. A second side of the substrate provides a substantially flat external surface of the overlay capable of fusing to a conforming surface in the presence of heat and pressure without an adhesive. Optionally, the overlay is laser-engraved so as to form ablated voids in the metal coating and carbonize the laser engravable polycarbonate under the ablated voids. | 04-04-2013 |